Sterol/Stanol Health Claim Comment Period Reopening Likely, FDA Says
This article was originally published in The Tan Sheet
Executive Summary
FDA likely will reopen the comment period on its interim final rule approving a health claim for sterol/stanol esters and coronary heart disease risk reduction, the agency said.
You may also be interested in...
Benecol, Take Control Marketing Highlight Approved CHD Health Claims
McNeil Consumer Healthcare's Benecol spread will soon be carrying labeling stating it can reduce the risk of coronary heart disease, the company said. The new labeling follows FDA's Sept. 8 approval of McNeil's health claim petition.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands